Comparative Pharmacology
Head-to-head clinical analysis: SCANDONEST PLAIN versus XYLOCAINE 5 W GLUCOSE 7 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SCANDONEST PLAIN versus XYLOCAINE 5 W GLUCOSE 7 5.
SCANDONEST PLAIN vs XYLOCAINE 5% W/ GLUCOSE 7.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Scandonest Plain (mepivacaine) is an amide-type local anesthetic that stabilizes neuronal membranes by binding to voltage-gated sodium channels, inhibiting sodium influx and blocking nerve impulse conduction.
Lidocaine is an amide-type local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses.
Dental infiltration: 1-2 mL (20-40 mg mepivacaine). Nerve block: 2-4 mL (40-80 mg). Max dose: 400 mg (approx 7 mg/kg). Do not repeat within 2 hours.
Adult: 5-25 mL (250-1250 mg lidocaine) of 5% lidocaine with glucose 7.5% solution, administered by caudal or lumbar epidural injection, single dose. Max total dose: 1250 mg.
None Documented
None Documented
Terminal elimination half-life: 1.9–3.2 hours in healthy adults; prolonged to 6–8 hours in hepatic impairment or severe renal disease; clinically meaningful for redosing intervals.
1.5-2 hours (terminal); prolonged in heart failure, hepatic disease, or elderly; neonates 3-6 hours due to immature hepatic function.
Renal excretion of unchanged drug and metabolites accounts for >95% of elimination; approximately 80% as unchanged mepivacaine and 15% as N-demethylated metabolites; biliary/fecal excretion minimal (<5%).
Hepatic metabolism (90% N-dealkylation by CYP1A2/CYP3A4 to monoethylglycinexylidide and glycinexylidide); renal excretion of metabolites and parent drug (<10% unchanged); <1% biliary/fecal.
Category C
Category C
Local Anesthetic
Local Anesthetic